Posts

Posted on

/C O R R E C T I O N — TELUS Communications Inc./

Canada NewsWire

In the news release, TELUS Sovereign AI Factory named Canada’s fastest and most powerful supercomputer, issued 17-Nov-2025 by TELUS Communications Inc. over PR Newswire, we are advised by the company that in the fourth paragraph, the word teraFLOPS has been updated to read petaFLOPS. The complete, corrected release follows:

TELUS Sovereign AI Factory named Canada’s fastest and most powerful supercomputer

TELUS takes top honours with global TOP500 recognition, proving that Canadian-owned infrastructure is among the world’s best


VANCOUVER, BC
, Nov. 17, 2025 /CNW/ – TELUS today announced that the TELUS Sovereign AI Factory in Rimouski, Quebec has been named Canada’s fastest and most powerful supercomputer by the prestigious TOP500 list, which ranks the world’s 500 most powerful computing systems, making TELUS the only telecom provider in Canada to receive this distinction. This recognition marks a groundbreaking achievement for Canadian technology innovation – proving that Canadian-owned and operated infrastructure can deliver world-class computational power while keeping data, innovation and economic benefits firmly within Canadian borders.

“This international recognition of TELUS’ Sovereign AI Factory as the fastest and most powerful supercomputer in Canada and 78th in the world represents a defining moment for TELUS and for our country’s position in the rapidly advancing global technology landscape,” said Darren Entwistle, President and CEO of TELUS. “This acknowledgment further reinforces that Canada’s advanced sovereign infrastructure can compete with – and indeed surpass – the most formidable supercomputers on the planet. Building on the robust data strategy TELUS initiated more than 25 years ago, our significant investments in high-performance computing have positioned TELUS to provide the secure, sovereign foundation our country needs to create made-in-Canada solutions, accelerate growth and advance our competitiveness in the global digital economy for generations to come. Importantly, TELUS is the only provider in Canada with the capability to provide Canadian-controlled, end-to-end digital solutions, combined with our team’s unparalleled expertise in AI-powered client experience solutions. TELUS’ inclusion on the TOP500 list clearly illustrates our deeply rooted passion for leveraging the potent power of technology innovation to improve outcomes for the millions of customers we serve globally.”

The TOP500 list is the global standard for high-performance computing and evaluates a supercomputer’s ability to solve complex sets of mathematical equations. It employs the High-Performance LINPACK (HPL) to measure how many calculations a system can complete per second, with results expressed in floating-point operations per second (FLOPS).

The TELUS Sovereign AI Factory, designed and implemented in partnership with HPE and powered by NVIDIA H200 GPUs and NVIDIA Quantum-2 InfiniBand, achieved a performance score of 22.74 petaFLOPS, ranking 78th overall by demonstrating exceptional capability in solving complex mathematical equations and performing floating-point operations, calculations involving very large or very small numbers common in scientific and engineering applications, at extraordinary speeds. Representing 22.74 quadrillion calculations per second, the immense processing power delivered by its Sovereign AI Factory positions TELUS at the forefront of organizations capable of handling the most demanding computational tasks in scientific research, artificial intelligence and advanced data analytics.

“TELUS’ industry-leading sovereign AI system was designed by HPE to apply our supercomputing expertise to advance public and private sector innovation,” said Trish Damkroger, senior vice president and general manager, HPC & AI Infrastructure Solutions at HPE. “Powered by HPE ProLiant Compute XD, the TELUS Sovereign AI Factory is playing a critical role in helping Canadian organizations solve engineering problems and drive scientific breakthroughs that are changing people’s lives for the better.”

The supercomputing infrastructure will enable Canada to accelerate breakthroughs across multiple domains, such as:

  • Artificial intelligence and machine learning: Training, fine-tuning and inferencing advanced AI models for enhanced customer experiences and business solutions
  • Healthcare innovation: Supporting complex medical research, drug discovery and genomic analysis
  • Climate modeling: Contributing to environmental sustainability through sophisticated climate prediction and analysis
  • Network optimization: Enhancing telecommunications infrastructure and service delivery through advanced computational modeling

Since 1993, the TOP500 project has provided a reliable basis for tracking and detecting trends in high performance computing. Twice a year, it publishes a list of the world’s 500 most powerful computer systems, providing the most accurate and historically consistent ranking of general-purpose HPC systems used for high-end applications.

This achievement underscores TELUS’ dedication to advancing Canadian technology leadership and creating opportunities for researchers, businesses, and institutions to access world-class computational resources, fostering collaboration and innovation across the country.

About TELUS

TELUS (TSX: T, NYSE: TU) is a world-leading communications technology company operating in more than 45 countries and generating over $20 billion in annual revenue with more than 20 million customer connections through our advanced suite of broadband services for consumers, businesses and the public sector. We are committed to leveraging our technology to enable remarkable human outcomes. TELUS is passionate about putting our customers and communities first, leading the way globally in client service excellence and social capitalism. TELUS Health is enhancing more than 160 million lives across 200 countries and territories through innovative preventive medicine and well-being technologies. TELUS Agriculture & Consumer Goods utilizes digital technologies and data insights to optimize the connection between producers and consumers. TELUS Digital specializes in digital customer experiences and future-focused digital transformations that deliver value for their global clients. Guided by our enduring ‘give where we live’ philosophy, TELUS, our team members and retirees have contributed $1.8 billion in cash, in-kind contributions, time and programs including 2.4 million days of service since 2000, earning us the distinction of the world’s most giving company.

For more information, visit telus.com or follow @TELUSNews on X and @Darren_Entwistle on Instagram.

For more information, please contact

TELUS Media Relations

Tricia Lo


[email protected]
 

SOURCE TELUS Communications Inc.

Posted on

Pony.ai Announces Gen-4 Autonomous Truck Lineup, Set for Mass Production and Deployment in 2026

PR Newswire


BEIJING
, Nov. 18, 2025 /PRNewswire/ — Pony.ai, a global leader in autonomous driving technology, today announces its fourth-generation (Gen-4) autonomous truck lineup, jointly developed with manufacturing partners including SANY Truck.

The Gen-4 autonomous trucks system will utilize 100% automotive-grade components, reducing the bill-of-materials (BOM) cost per vehicle by approximately 70% compared to the previous generation. By leveraging the majority of components from the latest-generation Robotaxi solution, the system is designed for a service life of 20,000 hours, supporting up to 1 million kilometers of freight operation.

The first two models will be built on battery-electric vehicle platforms. These models are designed for mass production on the thousand-unit scale, with initial fleet deployment expected in 2026.

By adopting the fully redundant design and safety standards utilized in Pony.ai’s latest generation Robotaxi, the Gen-4 autonomous trucks will elevate the safety and reliability of autonomous freight transport to a new level. They will be equipped with a fully redundant drive-by-wire chassis, featuring comprehensive redundancy across six key systems—steering, braking, communication, power supply, computing, and sensors—ensuring safe operation under various conditions. These trucks will also undergo rigorous testing, including electromagnetic compatibility, reliability, high-temperature, and extreme-cold tests, to handle complex road conditions and harsh weather commonly encountered in freight scenarios, further enhancing safety.

China, the world’s largest long-haul trucking market, is accelerating its transition toward intelligent logistics. Upon deployment, the Gen-4 autonomous trucks are expected to significantly lower costs and increase efficiency in freight logistics. For example, the “1+4” platooning solution, where one lead truck is human-driven followed by four driverless trucks, is projected to reduce freight cost per kilometer by 29% and increase profit margin by 195% compared to traditional freight, based on current trial scenarios. In addition, it is projected to reduce per-vehicle carbon emissions by about 60 tons annually, setting new industry benchmarks in safety, efficiency, and sustainability.

Since entering the autonomous truck market in 2018, Pony.ai has expanded its fleet to around 200 trucks, accumulated over 1 billion ton-kilometers of freight transport, and secured the first or among the first autonomous truck road test permits and freight transport operation licenses in multiple regions across China. 

 

Cision View original content:https://www.prnewswire.com/news-releases/ponyai-announces-gen-4-autonomous-truck-lineup-set-for-mass-production-and-deployment-in-2026-302618804.html

SOURCE Pony.ai

Posted on

NUTEX HEALTH REPORTS JUNE 30, 2025 SECOND QUARTER AND YEAR-TO-DATE FINANCIAL RESULTS

PR Newswire


  • Total revenue of $455.8 million for the first half of 2025
     versus $143.5 million for the first half of 2024, an increase of 217.5%

  • Net income attributable to Nutex Health Inc. of $3.5 million for the first half of 2025 versus net loss of $0.7 million for the first half of 2024, an increase of $4.2 million

  • Diluted income per share of $0.55 for the first half of 2025 versus a loss per share of $0.15 for the first half of 2024

  • EBITDA of $51.1 million for the first half of 2025 versus $15.6 million for the first half of 2024, an increase of 227.4%

  • Adjusted EBITDA of $144.4 million for the first half of 2025 versus $6.4 million for the first half of 2024, an increase


     of 2144.2%

  • Net cash from operating activities of $78.2 million for the first half of 2025

  • On August 14, 2025


    ,
     the Board of Directors authorized a stock repurchase program of up to $25.0 million of the Company’s common stock


HOUSTON
, Nov. 18, 2025 /PRNewswire/ — Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), today announced financial results for the three and six months ended June 30, 2025. Nutex Health is a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks.

Financial highlights for the three months ended
June 30, 2025:

  • Total revenue increased $167.9 million to $244.0 million for the three months ended June 30, 2025 as compared to total revenue of $76.1 million for the same period in 2024, an increase of 220.7%. Revenue from mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 203.2% in 2025 compared to 2024.
  • Total stock-based compensation expense for the three months ended June 30, 2025 was $78.7 million, an increase of approximately $78.8 million compared to the same period in 2024. Approximately 99% of total stock-based compensation expense of $78.7 million is due to the one-time obligations for under-construction and ramping hospitals.
  • Operating income for the three months ended June 30, 2025 was $33.7 million compared to $5.3 million for the same period in 2024, representing a $28.4 million improvement year over year.
  • Net loss attributable to Nutex Health for the three months ended June 30, 2025 of $17.7 million as compared to net loss attributable to Nutex Health of $0.4 million for the same period in 2024. The $17.7 million in net loss includes non-cash stock-based compensation expense of $78.7 million, while the $0.4 million net loss includes no non-cash stock-based compensation expense.
  • EBITDA attributable to Nutex Health of $(0.5) million, as compared to EBITDA attributable to Nutex Health of $8.5 million for the three months ended June 30, 2024, a decrease of 105.4%.
  • Adjusted EBITDA attributable to Nutex Health of $71.6 million, as compared to Adjusted EBITDA attributable to Nutex Health of $6.8 million for the three months ended June 30, 2024.
  • Total visits at the Hospital Division were 45,573 for the three months ended June 30, 2025, as compared to 41,208 for the same period in 2024, an increase of 4,365 or 10.6%. Visits at mature hospitals increased by 0.6% in the three months ended June 30, 2025 as compared to the same period in 2024.
  • Net cash from operating activities of $27.3 million for the three months ended June 30, 2025.
  • As of June 30, 2025, the Company had total assets of $841.0 million, including cash and cash equivalents of $96.7 million, and long-term debt, net of $20.5 million.

Financial highlights for the six months ended
June 30, 2025:

  • Total revenue increased $312.2 million to $455.8 million for the six months ended June 30, 2025 as compared to total revenue of $143.5 million for the same period in 2024, an increase of 217.5%. Revenue from mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 195.2% in 2025 compared to 2024.
  • Total stock-based compensation expense for the six months ended June 30, 2025 was $106.4 million, an increase of approximately $106.4 million compared to the same period in 2024. Approximately 99% of total stock-based compensation expense of $106.4 million is due to the one-time obligations for under-construction and ramping hospitals.
  • Operating income for the six months ended June 30, 2025 was $114.3 million compared to $6.7 million for the same period in 2024, representing a $107.6 million improvement year over year.
  • Net income attributable to Nutex Health for the six months ended June 30, 2025 of $3.5 million as compared to net loss attributable to Nutex Health of $0.7 million for the same period in 2024. The $3.5 million in net income includes non-cash stock-based compensation expense of $106.4 million, while the $0.7 million net loss includes no non-cash stock-based compensation expense.
  • EBITDA attributable to Nutex Health of $51.1 million, as compared to EBITDA attributable to Nutex Health of $15.6 million for the six months ended June 30, 2024, an increase of 227.4%.
  • Adjusted EBITDA attributable to Nutex Health of $144.4 million, as compared to Adjusted EBITDA attributable to Nutex Health of $6.4 million for the six months ended June 30, 2024.
  • Total visits at the Hospital Division were 93,842 for the six months ended June 30, 2025, as compared to 81,276 for the same period in 2024, an increase of 12,566 or 15.5%. Visits at mature hospitals increased by 3.0% in the six months ended June 30, 2025 as compared to the same period in 2024.
  • Net cash from operating activities of $78.2 million for the six months ended June 30, 2025.

Share Repurchase Program

On August 14, 2025, the Board of Directors authorized a stock repurchase program of up to $25.0 million of the Company’s common stock over the next six months. We anticipate executing this program opportunistically pending compliance with the Company’s current reporting obligations.

The purpose of the share repurchase program is to increase shareholder value and offset dilution from the issuance of additional shares related to stock compensation obligations for under-construction and ramping hospitals. Pursuant to the stock repurchase program, the Company may repurchase, from time to time, up to an aggregate of $25.0 million of the its outstanding shares of common stock, exclusive of any fees, commissions or other expenses related to such repurchases. The stock repurchase program permits the Company to repurchase shares of common stock at any time or from time to time at management’s discretion in open market transactions made in accordance with the provisions of Rule 10b-18 and/or Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, privately negotiated transactions or by other means in accordance with applicable securities laws.

The timing of any repurchases and the number of shares repurchased are subject to the discretion of the Company and may be affected by various factors, including general market and economic conditions, the market price of the Company’s common stock, the Company’s earnings, financial condition, capital requirements and levels of indebtedness, legal requirements, and other factors that management may deem relevant. The share repurchase program authorization does not obligate the Company to acquire any shares of its common stock and may be amended, suspended or discontinued at any time.

Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.

“We are pleased to report 217.5% revenue growth, Adjusted EBITDA attributable to Nutex Health of $144.4 million, a 643.5% increase in gross profit and a record high cash balance of $96.7 million, highlighting the company’s continued financial strength and solid fundamentals as we execute on our growth plan for 2025,” stated Jon Bates, Chief Financial Officer of Nutex Health.

“The arbitration process that we started in 2024 is now an ongoing part of our revenue cycle management process. In addition, the Company believes its shares are currently undervalued, and our share repurchase program underscores our confidence in the long-term prospects of Nutex Health. We anticipate executing this program opportunistically over the next several months with the goal of driving increased earnings per share and total shareholder return,” stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.

For more details on the Company’s financial results for the three and six months ended June 30, 2025, please refer to our Quarterly Report on Form 10-Q filed with the U.S. Securities & Exchange Commission and accessible at www.sec.gov.


NUTEX HEALTH INC.


CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)


(In thousands, except share and per share amounts)


June 30, 2025


December 31,
2024


Assets

Current assets:

Cash and cash equivalents

$             96,733

$                  40,640

Restricted short-term investments

—

2,941

Accounts receivable

349,220

232,449

Accounts receivable – related parties

5,737

3,602

Inventories

2,275

2,850

Prepaid expenses and other current assets

19,060

9,997

Total current assets

473,025

292,479

Property and equipment, net

82,915

77,933

Operating lease right-of-use assets

27,751

27,872

Financing lease right-of-use assets

215,398

218,889

Intangible assets, net

14,880

15,530

Goodwill, net

13,919

13,919

Deferred tax assets

12,852

7,987

Other assets

288

711

Total assets

$           841,028

$                655,320


Liabilities and Equity

Current liabilities:

Accounts payable

$             28,076

$                    9,614

Accounts payable – related parties

1,975

806

Lines of credit

7,859

3,554

Current portion of long-term debt

18,951

14,395

Operating lease liabilities, current portion

2,087

2,080

Financing lease liabilities, current portion

7,072

7,705

Accrued arbitration expenses

68,785

47,742

Accrued income tax expense

8,364

26,533

Accrued stock-based compensation

24,173

16,356

Accrued expenses and other current liabilities

27,532

25,440

Total current liabilities

194,874

154,225

Long-term debt, net

20,463

22,466

Operating lease liabilities, net

30,805

30,617

Financing lease liabilities, net

258,009

259,479

Total liabilities

504,151

466,787

Commitments and contingencies (Note 10)

Equity:

Common stock, $0.001 par value; 950,000,000 shares authorized; 6,595,109 and 5,511,452 shares     
issued and outstanding as of June 30, 2025 and December 31, 2024, respectively

7

6

Additional paid-in capital

588,699

489,409

Accumulated deficit

(353,456)

(356,976)

Nutex Health Inc. equity

235,250

132,439

Noncontrolling interests

101,627

56,094

Total equity

336,877

188,533

Total liabilities and equity

$           841,028

$                655,320

 


NUTEX HEALTH INC.


CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)


Three Months Ended June 30,


Six Months Ended June 30,


(In thousands, except share and per share amounts)


2025


2024


2025


2024

Revenue:

Hospital division

$         236,302

$           67,605

$         440,249

$         127,634

Population health management division

7,683

8,477

15,525

15,902

Total revenue

243,985

76,082

455,774

143,536

Operating costs and expenses:

Payroll

36,284

28,398

71,144

55,401

Contract services

61,109

9,505

99,764

20,825

Medical supplies

4,812

3,589

8,613

8,911

Depreciation and amortization

5,248

4,533

10,340

8,719

Other

11,608

7,496

22,651

16,962

Total operating costs and expenses

119,061

53,521

212,512

110,818

Gross profit

124,924

22,561

243,262

32,718

Corporate and other costs:

Stock-based compensation

78,747

(61)

106,389

(12)

Impairment of assets

—

3,474

—

3,474

Impairment of goodwill

—

3,197

—

3,197

General and administrative expenses

12,498

10,652

22,533

19,310

Total corporate and other costs

91,245

17,262

128,922

25,969

Operating income

33,679

5,299

114,340

6,749

Interest expense, net

5,678

5,054

11,798

9,499

Gain on warrant liability

—

(3,060)

—

(5,661)

Other (income) expense

4,269

(599)

7,594

(840)

Income before taxes

23,732

3,904

94,948

3,751

Income tax expense

7,588

894

27,998

1,283

Net income

16,144

3,010

66,950

2,468

Less: net income attributable to noncontrolling interests     

33,841

3,374

63,430

3,196

Net income (loss) attributable to Nutex Health Inc.

$          (17,697)

$               (364)

$              3,520

$               (728)

Income (loss)  per common share

Basic

$              (2.95)

$              (0.07)

$                0.60

$              (0.15)

Diluted

$              (2.95)

$              (0.07)

$                0.55

$              (0.15)

 


NUTEX HEALTH INC.


CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)


Six Months Ended June 30,


(In thousands)


2025


2024

Cash flows from operating activities:

Net income

$             66,950

$               2,468

Adjustment to reconcile net income to net cash from operating activities:     

Depreciation and amortization

10,340

8,719

Gain on warrant liability

—

(5,661)

Impairment of assets

—

3,474

Impairment of goodwill

—

3,197

Derecognition of goodwill

—

453

Stock-based compensation expense

106,389

(12)

Changes to deferred taxes

(4,865)

(2,341)

Debt accretion expense

504

579

Changes in operating assets and liabilities:

(Increase)/Decrease in Accounts receivable

(116,768)

(2,149)

(Increase)/Decrease in Accounts receivable – related party

(2,135)

(425)

(Increase)/Decrease in Inventories

575

631

(Increase)/Decrease in Prepaid expenses and other current assets

(8,640)

(1,693)

(Increase)/Decrease in Operating right-of-use assets

121

162

Increase/(Decrease) in Accounts payable

19,334

(1,617)

Increase/(Decrease) in Accounts payable – related party

1,169

414

Increase/(Decrease) in Operating lease liabilities

194

(370)

Increase/(Decrease) in Accrued arbitration expenses

21,043

—

Increase/(Decrease) in Accrued income tax expense

(18,169)

—

Increase/(Decrease) in Accrued expenses and other current liabilities

2,180

10,482

Net cash provided by operating activities

78,222

16,311

Cash flows from investing activities:

Acquisitions of property and equipment

(815)

(1,292)

Proceeds from restricted short-term investment

2,941

—

Cash related to sale of business

—

(711)

Cash related to asset acquisition

(1,994)

—

Net cash used in investing activities

132

(2,003)

Cash flows from financing activities:

Proceeds from lines of credit

4,606

132

Proceeds from notes payable

258

4,915

Repayments of lines of credit

(301)

(594)

Repayments of notes payable

(5,697)

(6,157)

Repayments of finance leases

(2,593)

(1,440)

Proceeds from common stock issuance, net issuance costs

—

9,203

Members’ contributions

242

301

Members’ distributions

(18,776)

(1,862)

Net cash provided by (used in) financing activities

(22,261)

4,498

Net increase in cash and cash equivalents

56,093

18,806

Cash and cash equivalents – beginning of the period

40,640

22,002

Cash and cash equivalents – end of the period

$             96,733

$             40,808

Non-GAAP Financial Measures (Unaudited)

EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe EBITDA and Adjusted EBITDA are useful because it allows us to more effectively evaluate our operating performance.

We define EBITDA as net income (loss) attributable to Nutex Health Inc. plus interest expense, income taxes, depreciation and amortization.

We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plus net interest expense, income taxes, depreciation and amortization, further adjusted for stock-based compensation, certain defined items of expense and any acquisition-related costs and impairments. Interest expense includes interest on lease liabilities, which is a component of total finance lease cost. A reconciliation of net income (loss) to Adjusted EBITDA is included below.

Beginning in the first quarter of 2025, we updated our presentation of Adjusted EBITDA to separately disclose finance lease payments related to leases under ASC 842. We believe this change provides greater transparency into our operating performance.

Adjusted EBITDA is not intended to serve as an alternative to U.S. GAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies. Adjusted EBITDA follows (in thousands):


Three Months Ended June 30,


2025


2024

Reconciliation of net loss attributable to Nutex Health Inc. to     
Adjusted EBITDA:


(Updated)


(Prior)


(Updated)


(Prior)

Net loss attributable to Nutex Health Inc.

$          (17,697)

$          (17,697)

$               (364)

$               (364)

Depreciation and amortization

5,248

5,248

4,533

4,533

Interest expense, net

5,678

5,678

5,055

5,055

Income tax expense

7,588

7,588

893

893

Allocation to noncontrolling interests

(1,275)

(1,275)

(1,628)

(1,628)

EBITDA

(458)

(458)

8,489

8,489

Gain on warrant liability

—

—

(3,060)

(3,060)

Impairment of assets

—

—

3,474

3,474

Impairments of goodwill

—

—

3,197

3,197

Finance lease payments(1)

(6,675)

—

(5,191)

—

Stock-based compensation

78,747

78,747

(61)

(61)

Adjusted EBITDA

$           71,614

$           78,289

$              6,848

$           12,039


Six Months Ended June 30,


2025


2024

Reconciliation of net income (loss) attributable to Nutex     
Health Inc. to Adjusted EBITDA:


(Updated)


(Prior)


(Updated)


(Prior)

Net income (loss) attributable to Nutex Health Inc.

$              3,520

$              3,520

$               (728)

$               (728)

Depreciation and amortization

10,340

10,340

8,719

8,719

Interest expense, net

11,798

11,798

9,499

9,499

Income tax expense

27,998

27,998

1,283

1,283

Allocation to noncontrolling interests

(2,572)

(2,572)

(3,172)

(3,172)

EBITDA

51,084

51,084

15,601

15,601

Gain on warrant liability

—

—

(5,661)

(5,661)

Impairment of assets

—

—

3,474

3,474

Impairment of goodwill

—

—

3,197

3,197

Finance lease payments(1)

(13,038)

—

(10,163)

—

Stock-based compensation

106,389

106,389

(12)

(12)

Adjusted EBITDA

$         144,435

$         157,473

$              6,436

$           16,599


(1)   

Finance lease payments consist of cash payments for financing leases under ASC 842, which should be deducted from EBITDA. We believe this change is useful to investors to evaluate the ongoing operating performance of our business.

About Nutex Health Inc.

Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.

The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states.

The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups.

Forward-Looking Statements

Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Report on Form 10-Q for the three and six months ended June 30, 2025 under the heading “Risk Factors” in Part II, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.

Cision View original content:https://www.prnewswire.com/news-releases/nutex-health-reports-june-30-2025-second-quarter-and-year-to-date-financial-results-302619385.html

SOURCE Nutex Health, Inc.

Posted on

NUTEX HEALTH REPORTS RESTATED FIRST QUARTER 2025 FINANCIAL RESULTS

PR Newswire


  • Total revenue of $211.8 million for Q1 2025


    versus $67.5 million for Q1 2024, an increase of 214.0%

  • Net income attributable to Nutex Health Inc. of $21.2 million for Q1 2025 versus net loss of $0.4 million for Q1 2024, an increase of $21.6 million.

  • Diluted income per share of $3.33 for Q1 2025 versus a loss per share of $0.08 for Q1 2024

  • EBITDA of $51.5 million for Q1 2025 versus $7.1 million for Q1 2024, an increase of 624.7%

  • Adjusted EBITDA of $72.8 million for Q1 2025 versus $(0.4) million for Q1 2024, an increase


    of $73.2 million

  • Net cash from operating activities of $51.0 million for Q1 2025

  • The Company believes its arbitration efforts through the Independent Dispute Resolution (IDR) process have resulted in an increase in fair and reasonable payments from insurance companies


HOUSTON
, Nov. 18, 2025 /PRNewswire/ — Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), today announced restated first quarter financial results for the three months ended March 31, 2025. Nutex Health is a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks.

First Quarter 2025 Restatement Background

As previously disclosed in Form 8-K filed on August 21, 2025, the Audit Committee of the Board of Directors of Nutex Health, after consultation with the Chief Financial Officer, concluded that the Company’s previously issued condensed consolidated unaudited financial statements as of and for the three months ended March 31, 2025 contained in the originally filed Form 10-Q should be restated for the items described below. The major balance sheet accounts affected by these non-cash adjustments are as follows:

  • Corrected the classification of non-cash, stock-based compensation obligations totaling $20.7 million related to under construction and ramping hospitals from equity to liabilities.
  • Reclassified related-party accounts payable balances of $3.5 million from liabilities to equity.
  • Reclassified $2.9 million of restricted balances out of cash and cash equivalents and into short-term investments.
  • Increased accrued income tax expense by $2.4 million.

These adjustments as of March 31, 2025, when compared to the previously issued financial statements, result in an overall net increase to liabilities, a similar decrease to equity and an increase in net income. Total liabilities as of March 31, 2025 increased by $19.6 million (4.0%) while total equity correspondingly decreased by $19.6 million (7.1%). Net income for the period ended March 31, 2025 increased by $6.6 million (14.9%). As restated, earnings per share, diluted by unvested restricted stock and contingently issuable stock compensation increased by $0.77 to $3.33 from $2.56, while earnings per share, basic increased $1.09 to $3.74 from $2.65 for the three months ended March 31, 2025. These adjustments are non-cash in nature, had no material effect on key metrics including revenue, liquidity, short-term and long-term debt, operating cash flow, adjusted EBITDA or number of patient visits as of and for the periods presented therein.

Financial highlights for the
three months ended March 31, 2025
 (as restated):

  • Total revenue increased $144.3 million to $211.8 million for the three months ended March 31, 2025 as compared to total revenue of $67.5 million for the same period in 2024, an increase of 214.0%. Revenue from mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 186.5% in 2025 compared to 2024.
  • Total stock-based compensation expense for the three months ended March 31, 2025 was $27.6 million compared to less than $0.1 million for the same period in 2024. Approximately 99% of total stock-based compensation expense of $27.6 million is due to the one-time obligations for under-construction and ramping hospitals.
  • Operating income for the three months ended March 31, 2025 was $80.7 million compared to $1.5 million for the same period in 2024, representing a $79.2 million improvement year over year.
  • Net income attributable to Nutex Health for the three months ended March 31, 2025 of $21.2 million as compared to net loss attributable to Nutex Health of $0.4 million for the same period in 2024. The $21.2 million in net income includes non-cash stock-based compensation expense of $27.6 million, while the $0.4 million net loss includes no non-cash stock-based compensation expense.
  • EBITDA attributable to Nutex Health of $51.5 million, as compared to EBITDA attributable to Nutex Health of $7.1 million for the three months ended March 31, 2024, an increase of 624.7%.
  • Adjusted EBITDA attributable to Nutex Health of $72.8 million, as compared to Adjusted EBITDA attributable to Nutex Health of $(0.4) million for the three months ended March 31, 2024.
  • Total visits at the Hospital Division were 48,269 for the three months ended March 31, 2025, as compared to 40,068 for the same period in 2024, an increase of 8,201 or 20.5%. Visits at mature hospitals increased by 5.3% in the three months ended March 31, 2025 as compared to the same period in 2024.
  • Net cash from operating activities of $51.0 million for the three months ended March 31, 2025.
  • As of March 31, 2025, the Company had total assets of $761.9 million, including cash and cash equivalents of $84.7 million, and long-term debt, net of $21.7 million.

Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.

“We are excited to provide yet another solid quarter with $21.2 million in net income attributable to Nutex, a record high gross profit of 55.9%, a record high $51.0 million in net cash from operating activities and a record high cash balance of $84.7 million, all on a restated basis and materially the same as originally reported, highlighting the Company’s continued financial strength and solid fundamentals as we execute on our growth plan for 2025,” stated Jon Bates, Chief Financial Officer of Nutex Health.

“The great momentum that we started in 2024 is continuing into the first quarter of 2025. We are now seeing more consistent financial results stemming from a combination of volume growth and operational efficiency, with more fair and reasonable payments from the arbitration process. We would like to thank our team of physicians and team members nationwide for working in alignment to get us to where we are this quarter,” stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.

For more details on the Company’s restated financial results for the three months ended March 31, 2025, please refer to our Amended Quarterly Report on Form 10-Q/A filed with the U.S. Securities & Exchange Commission and accessible at www.sec.gov.

 


NUTEX HEALTH INC.


CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

 


(In thousands, except share and per share amounts)


March 31, 2025


December 31, 2024


Assets

(As Restated)

Current assets:

Cash and cash equivalents

$           84,729

$           40,640

Restricted short-term investment

2,941

2,941

Accounts receivable

295,082

232,449

Accounts receivable – related parties

4,258

3,602

Inventories

3,118

2,850

Prepaid expenses and other current assets

11,389

9,997

Total current assets

401,517

292,479

Property and equipment, net

76,431

77,933

Operating right-of-use assets

27,466

27,872

Financing right-of-use assets

216,193

218,889

Intangible assets, net

15,205

15,530

Goodwill, net

13,919

13,919

Deferred tax assets

10,487

7,987

Other assets

698

711

Total assets

$         761,916

$         655,320


Liabilities and Equity

Current liabilities:

Accounts payable

$           19,836

$              9,614

Accounts payable – related parties

2,141

806

Lines of credit

7,126

3,554

Current portion of long-term debt

13,635

14,395

Operating lease liabilities, current portion

2,103

2,080

Financing lease liabilities, current portion

8,027

7,705

Accrued arbitration expenses

51,803

47,742

Accrued income tax expense

46,130

26,533

Accrued stock-based compensation

20,739

16,356

Accrued expenses and other current liabilities

24,639

25,440

Total current liabilities

196,179

154,225

Long-term debt, net

21,733

22,466

Operating lease liabilities, net

30,350

30,617

Financing lease liabilities, net

258,387

259,479

Total liabilities

506,649

466,787

Commitments and contingencies (Note 9)

Equity:

Common stock, $0.001 par value; 950,000,000 shares authorized; 5,950,539 and 5,511,452
shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively

6

6

Additional paid-in capital

512,701

489,409

Accumulated deficit

(335,759)

(356,976)

Nutex Health Inc. equity

176,948

132,439

Noncontrolling interests

78,319

56,094

Total equity

255,267

188,533

Total liabilities and equity

$         761,916

$         655,320

 


NUTEX HEALTH INC.


CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

 


Three Months Ended March 31,


(In thousands, except share and per share amounts)


2025


2024


(As Restated)

Revenue:

Hospital division

$               203,947

$                 60,029

Population health management division

7,842

7,424

Total revenue

211,789

67,453

Operating costs and expenses:

Payroll

34,860

27,003

Contract services

38,655

11,319

Medical supplies

3,801

5,322

Depreciation and amortization

5,092

4,186

Other

11,043

9,466

Total operating costs and expenses

93,451

57,296

Gross profit

118,338

10,157

Corporate and other costs:

Stock-based compensation

27,642

49

General and administrative expenses

10,035

8,658

Total corporate and other costs

37,677

8,707

Operating income (loss)

80,661

1,450

Interest expense, net

6,120

4,444

Gain on warrant liability

—

(2,601)

Other (income) expense

3,325

(241)

Income (loss) before taxes

71,216

(152)

Income tax expense

20,410

390

Net income (loss)

50,806

(542)

Less: net income (loss) attributable to noncontrolling interests

29,589

(178)

Net income (loss) attributable to Nutex Health Inc.

$                 21,217

$                     (364)

Earnings (loss) per common share

Basic

$                      3.74

$                    (0.08)

Diluted

$                      3.33

$                    (0.08)

 


NUTEX HEALTH INC.


CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

 


Three Months Ended March 31,


(In thousands)


2025


2024

Cash flows from operating activities:


(As Restated)

Net income (loss)

$                   50,806

$                      (542)

Adjustment to reconcile net income (loss) to net cash from operating activities:

Depreciation and amortization

5,092

4,186

Gain on warrant liability

—

(2,601)

Stock-based compensation expense

27,642

49

Changes to deferred taxes

(2,500)

(95)

Debt accretion expense

253

365

Changes in operating assets and liabilities:

Accounts receivable

(62,633)

(2,909)

Accounts receivable – related party

(656)

(62)

Inventories

(268)

415

Prepaid expenses and other current assets

(1,378)

796

Operating right-of-use assets

406

273

Accounts payable

10,222

(1,681)

Accounts payable – related party

1,334

475

Operating lease liabilities

(245)

(376)

Accrued arbitration expenses

4,061

—

Accrued income tax expense

19,598

—

Accrued expenses and other current liabilities

(769)

4,758

Net cash from operating activities

50,965

3,051

Cash flows from investing activities:

Acquisitions of property and equipment

(64)

(733)

Net cash from investing activities

(64)

(733)

Cash flows from financing activities:

Proceeds from lines of credit

3,864

—

Proceeds from long-term debt

157

2,915

Repayments of lines of credit

(292)

(595)

Repayments of long-term debt

(1,810)

(4,388)

Repayments of finance leases

(1,367)

(968)

Proceeds from common stock issuance, net issuance costs

—

9,203

Members’ distributions

(7,364)

(481)

Net cash from financing activities

(6,812)

5,686

Net change in cash and cash equivalents

44,089

8,004

Cash and cash equivalents – beginning of the period

40,640

22,002

Cash and cash equivalents – end of the period

$                   84,729

$                   30,006

Non-GAAP Financial Measures (Unaudited)

EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe EBITDA and Adjusted EBITDA are useful because it allows us to more effectively evaluate our operating performance.

We define EBITDA as net income (loss) attributable to Nutex Health Inc. plus interest expense, income taxes, depreciation and amortization.

We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plus net interest expense, income taxes, depreciation and amortization, further adjusted for stock-based compensation, certain defined items of expense and any acquisition-related costs and impairments. Interest expense includes interest on lease liabilities, which is a component of total finance lease cost. A reconciliation of net income (loss) to Adjusted EBITDA is included below.

Beginning in the first quarter of 2025, we have updated our presentation of Adjusted EBITDA to separately disclose finance lease payments related to leases under ASC 842. We believe this change provides greater transparency into our operating performance.

Adjusted EBITDA is not intended to serve as an alternative to U.S. GAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies. Adjusted EBITDA follows (in thousands):


Three Months Ended March 31,


2025


2024

Reconciliation of net income (loss) attributable to Nutex
Health Inc. to Adjusted EBITDA:


(As restated,
updated)


(As restated,
prior)


(Updated)


(Prior)

Net income (loss) attributable to Nutex Health Inc.

$           21,217

$           21,217

$               (364)

$               (364)

Depreciation and amortization

5,092

5,092

4,186

4,186

Interest expense, net

6,120

6,120

4,444

4,444

Income tax expense

20,410

20,410

390

390

Allocation to noncontrolling interests

(1,297)

(1,297)

(1,544)

(1,544)

EBITDA

51,542

51,542

7,112

7,112

Gain on warrant liability

—

—

(2,601)

(2,601)

Finance lease payments(1)

(6,363)

—

(4,972)

—

Stock-based compensation

27,642

27,642

49

49

Adjusted EBITDA

$           72,821

$           79,184

$               (412)

$              4,560


(1)   

Finance lease payments consist of cash payments for financing leases under ASC 842, which should be deducted from EBITDA. We believe this change is useful to investors to evaluate the ongoing operating performance of our business.

About Nutex Health Inc.

Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.

The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states.

The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups.

Forward-Looking Statements

Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Report on Form 10-Q/A for the three months ended March 31, 2025 under the heading “Risk Factors” in Part II, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.

Cision View original content:https://www.prnewswire.com/news-releases/nutex-health-reports-restated-first-quarter-2025-financial-results-302619372.html

SOURCE Nutex Health, Inc.

Posted on

TON Strategy Company Welcomes Coinbase’s Launch of $TON Trading Across Global Platforms

TON Strategy Company Welcomes Coinbase’s Launch of $TON Trading Across Global Platforms

  • $TON spot trading begins November 18 on Coinbase International Exchange, Coinbase Advanced, and coinbase․com

  • Expands global liquidity, institutional access, and price-discovery across the $TON ecosystem

  • Follows recent $TON listings on Gemini, Robinhood, and Zengo, marking continued momentum across major platforms

LAS VEGAS–(BUSINESS WIRE)–
TON Strategy Company (NASDAQ: TONX), a digital asset treasury company dedicated to holding Toncoin ($TON), today welcomed Coinbase Markets’ announcement that $TON spot trading will begin across Coinbase’s retail, advanced, institutional, and international platforms.

Spot trading for $TON goes live on 18 November, 2025, with the $TON-USD trading pair opening on or after 9:00 a.m. PT, subject to liquidity conditions. $TON will be available on coinbase․com, the Coinbase mobile app, and Coinbase Advanced, with institutional access supported directly through Coinbase Exchange.

The listings represent another step in expanding global access to $TON, the native token of The Open Network (TON) – a high-throughput Layer-1 blockchain integrated with Telegram and designed to scale to more than a billion users. It also reflects growing institutional recognition of TON’s trajectory and underscores the ecosystem’s expansion across major global platforms.

“This is an encouraging development for the $TON ecosystem,” said Veronika Kapustina, Chief Executive Officer of TON Strategy Company. “Every new venue that lists $TON broadens access, deepens liquidity, and helps accelerate adoption where demand is already strong. TON is a major Layer-1 with meaningful real-world usage, and greater market attention always felt inevitable. We look forward to seeing custody and staking support expand over time as well — both are important components of a fully developed market infrastructure.”

Telegram’s Mini App economy continues to grow rapidly, with more than one billion users able to transact, earn, save, and hold digital assets directly inside the messenger. TON enables users to move value globally through low-cost, near-instant payments; maintain on-chain digital identity; interact with a widening universe of mini-apps and services; and participate in a global marketplace without a separate exchange account.

Today’s launch follows recent $TON trading expansions on Gemini, Robinhood, and Zengo, marking continued momentum across major platforms and strengthening the global market infrastructure surrounding $TON — from spot access to the building blocks of a deeper institutional ecosystem.

Against this backdrop of growing international adoption, TON Strategy Company continues to advance its long-term strategy of providing transparent, regulated access to the $TON ecosystem. The Company reported last week that, as of September 30, 2025, it held digital assets with a fair value of $588.2 million, supported by $53.9 million in cash and restricted cash. The treasury reached 217.8 million units of $TON, generating 336,000 units in staking rewards during the quarter and producing $707,000 in staking revenue through scaled validator operations. Total stockholders’ equity rose to $639.5 million, representing a book value of $10.82 per share – underscoring the Company’s disciplined execution, regulatory rigor, and commitment to delivering institutional-grade, long-only exposure to the TON ecosystem.

“As more regulated international exchanges support $TON, we see a reinforcing loop between real-world usage inside Telegram and the market infrastructure surrounding the asset,” Ms. Kapustina added. “With a strong balance sheet and long-term treasury position, TONX is well aligned with that momentum – and we believe it reflects rising global confidence in $TON’s trajectory.”

About TON Strategy Company

TON Strategy Company (Nasdaq: TONX) is focused on the accumulation of $TON – the native cryptocurrency of Telegram’s billion-user platform – for long-term investment, whether acquired through deployment of proceeds from capital raising activity, staking rewards or via open market purchases. The Company aims to steadily expand its $TON holdings, stake $TON, and support the development of a tokenized economy inside Telegram.

In addition, the Company continues to operate legacy business units, including MARKET.live, a multi-vendor livestream shopping platform, and LyveCom, an AI-powered social commerce innovator that enables brands and merchants to deliver omnichannel livestream shopping experiences across websites, apps, and social platforms.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical fact contained in this press release should be considered forward-looking statements, including, but not limited to, statements regarding: our business and growth strategy; market adoption; the performance of our products and benefits to customers; our estimated total addressable market, serviceable available market, and serviceable obtainable market. Without limiting the foregoing, in some cases, you can identify forward-looking statements by terms such as “aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.

Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: our incursion of significant net losses and uncertainty whether we will achieve or maintain profitable operations; our ability to grow and compete in the future, and to execute our business strategy; our decision to implement a cryptocurrency treasury strategy, whereby we acquire Toncoin, the native cryptocurrency of The Open Network (“TON”) blockchain and our dependence on TON and Toncoin as a result of this strategy; our ability to maintain and expand our customer base and to convince our customers to increase the use of our services and/or platform; our financial results and the market price of our common stock may be affected by the price of Toncoin, and our Toncoin holdings will be less liquid than cash and cash equivalents; changes in the broader digital asset regulatory landscape and as it relates to TON and Toncoin and our failure to comply with applicable regulatory requirements and risks related to any actions we may take to prevent or correct such failure; the availability of opportunities to stake Toncoin; the competitive market in which we operate; our ability to increase the number of our strategic relationships or grow the revenues received from our current strategic relationships; our ability to develop existing services or acceptable new services that keep pace with technological developments; our ability to successfully launch new product platforms, including MARKET.live, the rate of adoption of these platforms and the revenue generated from these platforms; our ability to deliver our services, as we depend on third party providers; our ability to attract and retain qualified management personnel; our susceptibility to cybersecurity incidents and other disruptions, particularly as it relates to our holdings of Toncoin; our ability to maintain compliance with the listing requirements of the Nasdaq Capital Market; the impact of, and our ability to operate our business and effectively manage our growth under evolving and uncertain global economic, political, and social trends, including legislation banning or otherwise hampering the digital asset landscape, inflation, rising interest rates, and recessionary concerns; and other important factors discussed in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, as any such factors may be updated from time to time in our other filings with the SEC, including, but not limited to our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, which are accessible on the SEC’s website at www.sec.gov and our Investor Relations page on our website at https://ir.tonstrat.com.

Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Contact Information

Cody Slach and Alec Wilson

Gateway Group, Inc.

[email protected]

949-574-3860

Media Contact Information

[email protected]

KEYWORDS: Nevada United States North America

INDUSTRY KEYWORDS: Software Professional Services Blockchain Fintech Payments Electronic Commerce Apps/Applications Technology Digital Cash Management/Digital Assets Cryptocurrency Web3 Finance

MEDIA:

Posted on

NUTEX HEALTH REPORTS RESTATED 2024 FINANCIAL RESULTS

PR Newswire

FULL YEAR 2024 HIGHLIGHTS:


  • Total revenue of $479.9 million for the year 2024 versus $247.6 million for the year 2023, an increase of 93.8%

  • Net income attributable to Nutex Health Inc. of $52.1 million for 2024 versus net loss of $45.8 million for 2023

  • Diluted income per share of $9.69 for 2024 versus a loss per share of $10.39 for 2023

  • EBITDA of $98.8 million for 2024 versus $(22.5) million for 2023

  • Adjusted EBITDA of $124.1 million for 2024 versus $10.8 million for 2023, an increase


    of 1046.1%

  • Net cash from operating activities of $23.2 million for the year 2024


HOUSTON
, Nov. 18, 2025 /PRNewswire/ — Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), today announced restated fourth quarter 2024 and fiscal year 2024 financial results for the twelve months ended December 31, 2024. Nutex Health is a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks.

Year 2024 Restatement Background

As previously disclosed in Form 8-K filed on August 21, 2025, the Audit Committee of the Board of Directors of Nutex Health, after consultation with the Chief Financial Officer, concluded that the Company’s previously issued consolidated financial statements as of and for the year ended December 31, 2024 contained in the originally filed Form 10-K should be restated for the items described below. The major balance sheet accounts affected by these non-cash adjustments are as follows:

  • Corrected the classification of non-cash, stock-based compensation obligations totaling $16.4 million related to under construction and ramping hospitals from equity to liabilities.
  • Reclassified related-party accounts payable balances of $3.5 million from liabilities to equity.
  • Reclassified $2.9 million of restricted balances out of cash and cash equivalents and into short-term investments.
  • Increased accrued income tax expense by $0.5 million.

These adjustments as of December 31, 2024, when compared to the previously issued financial statements, result in an overall net increase to liabilities, a similar decrease to equity, and a nominal decrease in net income. Total liabilities as of December 31, 2024 increased by $13.4 million (2.9%), while total equity correspondingly decreased by $13.4 million (6.6%). Net income for the year decreased by approximately $0.5 million (0.5%). As restated, earnings per share, diluted by unvested restricted stock and contingent issuable stock compensation decreased by $0.02 to $9.69 from $9.71, while earnings per share, basic decreased by $0.02 to $10.23 from $10.25 for the year ended December 31, 2024. These adjustments are non-cash in nature, had no material effect on key metrics including revenue, liquidity, short-term and long-term debt, operating cash flow, adjusted EBITDA or number of patient visits as of and for the periods presented therein, and had an immaterial impact on net income.

Financial highlights for the three months ended
December 31, 2024
 (as restated):

  • Total revenue increased $187.9 million to $257.6 million for the three months ended December 31, 2024 as compared to total revenue of $69.7 million for the same period in 2023, an increase of 269.8%. Revenue from mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 175.6% in 2024 compared to 2023.
  • Total stock-based compensation expense for the three months ended December 31, 2024 was $14.6 million, compared to less than $0.6 million for the same period in 2023. Approximately 99% of total stock-based compensation expense of $14.6 million was due to one-time obligations for under-construction and ramping hospitals.
  • Operating income (including the negative impact of $14.6 million in non-cash stock-based compensation expense) for the three months ended December 31, 2024 was $114.3 million, compared to an operating loss of $26.1 million for the same period in 2023, representing a $140.4 million improvement year over year.
  • Net income attributable to Nutex Health for the three months ended December 31, 2024 was $61.6 million as compared to net loss attributable to Nutex Health of $31.6 million for the same period in 2023. The $61.6 million in net income included non-cash stock-based compensation expense of $14.6 million, while the $31.6 million net loss included no non-cash stock-based compensation expense.
  • EBITDA attributable to Nutex Health was $78.9 million, as compared to EBITDA attributable to Nutex Health of $(27.7) million for the three months ended December 31, 2023, an increase of $106.6 million.
  • Adjusted EBITDA attributable to Nutex Health was $94.0 million, as compared to Adjusted EBITDA attributable to Nutex Health of $3.1 million for the three months ended December 31, 2023.
  • Total visits at the Hospital Division were 45,444 for the three months ended December 31, 2024, as compared to 41,381 for the same period in 2023, an increase of 4,063 or 9.8%. Visits at mature hospitals increased by 3.1% in the three months ended December 31, 2024 as compared to the same period in 2023.
  • Net cash from operating activities was $0.1 million for the three months ended December 31, 2024.
  • As of December 31, 2024, the Company had total assets of $655.3 million, including cash and cash equivalents of $40.6 million, and long-term debt, net of $22.5 million.

Financial highlights for the year ended
December 31, 2024
 (as restated):

  • Total revenue increased $232.3 million to $479.9 million for the year ended December 31, 2024, as compared to total revenue of $247.6 million for the same period in 2023, an increase of 93.8%. Revenue from mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 56.6% in 2024 compared to 2023.
  • Total stock-based compensation expense for the year ended December 31, 2024 was $16.6 million, compared to $2.8 million for the same period in 2023. Approximately 99% of total stock-based compensation expense of $16.6 million was due to one-time obligations for under-construction and ramping hospitals.
  • Operating income for the year ended December 31, 2024 was $130.7 million, compared to an operating loss of $31.8 million for the same period in 2023, representing a $162.5 million improvement year over year.
  • Net income attributable to Nutex Health for the year ended December 31, 2024 was $52.1 million, as compared to net loss attributable to Nutex Health of $45.8 million for the same period in 2023. The $52.1 million in net income included non-cash stock-based compensation expense of $16.6 million, while the $45.8 million net loss included no non-cash stock-based compensation expense.
  • EBITDA attributable to Nutex Health was $98.8 million, as compared to EBITDA attributable to Nutex Health of $22.5 million for the year ended December 31, 2023, an increase of $121.3 million.
  • Adjusted EBITDA attributable to Nutex Health was $124.1 million, as compared to Adjusted EBITDA attributable to Nutex Health of $10.8 million for the year ended December 31, 2023.
  • Total visits at the Hospital Division were 168,388 for the year ended December 31, 2024, as compared to 144,058 for the same period in 2023, an increase of 24,330 or 16.9%. Visits at mature hospitals increased by 6.5% in the year ended December 31, 2024 as compared to the same period in 2023.
  • Net cash from operating activities was $23.2 million for the year ended December 31, 2024.

Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.

“We are pleased to report 93.8% revenue growth, Adjusted EBITDA attributable to Nutex Health of $124.1 million, a 464.4% increase in gross profit and a record high cash balance of $40.6 million, all on a restated basis and materially the same as originally reported, highlighting the Company’s continued financial strength and solid fundamentals as we execute on our growth plan for 2025,” stated Jon Bates, Chief Financial Officer of Nutex Health.

“The arbitration process that we started in 2024 is now an ongoing part of our revenue cycle management process. In addition, the Company believes its shares are currently undervalued, and our previously announced stock repurchase program underscores our confidence in the long-term prospects of Nutex Health. We anticipate executing this program opportunistically with the goal of driving increased earnings per share and total shareholder return,” stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.

For more details on the Company’s restated financial results for the twelve months ended December 31, 2024, please refer to our Amended Annual Report on Form 10-K/A filed with the U.S. Securities & Exchange Commission and accessible at www.sec.gov.


NUTEX HEALTH INC.


CONSOLIDATED BALANCE SHEET


December 31,


2024


2023


Assets


(As restated)

Current assets:

  Cash and cash equivalents

$      40,640,616

$      22,002,056

  Restricted short-term investment

2,940,796

—

  Accounts receivable

232,449,226

58,624,301

  Accounts receivable – related parties

3,602,189

4,152,068

  Inventories

2,849,814

3,390,584

  Prepaid expenses and other current assets

9,996,244

2,679,394

Total current assets

292,478,885

90,848,403

Property and equipment, net

77,932,744

81,387,649

Operating right-of-use assets

27,871,830

11,853,082

Financing right-of-use assets

218,889,351

176,146,329

Intangible assets, net

15,530,281

20,512,636

Goodwill, net

13,918,719

17,066,263

Deferred tax assets

7,987,236

—

Other assets

711,347

431,135

Total assets

$    655,320,393

$    398,245,497


Liabilities and Equity

Current liabilities:

  Accounts payable

$        9,613,821

$      18,899,196

  Accounts payable – related parties

805,766

6,382,197

  Lines of credit

3,554,029

3,371,676

  Current portion of long-term debt

14,395,457

10,808,721

  Operating lease liabilities, current portion

2,079,940

1,579,987

  Financing lease liabilities, current portion

7,704,873

4,315,979

  Accrued arbitration expenses

47,741,815

—

  Accrued income tax expense

26,532,699

—

  Accrued stock based compensation

16,356,000

—

  Accrued expenses and other current liabilities

25,441,790

12,955,296

Total current liabilities

154,226,190

58,313,052

Long-term debt, net

22,465,896

26,314,733

Operating lease liabilities, net

30,617,399

15,479,639

Financing lease liabilities, net

259,479,096

213,886,213

Deferred tax liabilities

—

5,145,754

Total liabilities

466,788,581

319,139,391

Commitments and contingencies (Note 10)

Equity:

  Common stock, $0.001 par value; 950,000,000 shares authorized; 5,511,452 and 4,511,199
  shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively

5,511

4,511

  Additional paid-in capital

489,408,981

470,521,218

  Accumulated deficit

(356,976,499)

(409,072,539)

Nutex Health Inc. equity

132,437,993

61,453,190

Noncontrolling interests

56,093,819

17,652,916

Total equity

188,531,812

79,106,106

Total liabilities and equity

$    655,320,393

$    398,245,497

 


NUTEX HEALTH INC.


CONSOLIDATED STATEMENTS OF OPERATIONS


Year ended December 31,


2024


2023


2022


(As restated)

Revenue:

Hospital division

$   449,063,683

$  218,070,397

$   198,508,245

Population health management division

30,884,950

29,575,919

20,786,061

Total revenue

479,948,633

247,646,316

219,294,306

Operating costs and expenses:

Payroll

117,527,022

108,377,938

111,785,110

Contract services

100,757,191

42,349,982

35,913,441

Medical supplies

15,285,481

14,151,140

12,118,893

Depreciation and amortization

18,971,972

17,591,572

13,131,374

Other

31,145,690

30,401,513

30,923,750

Total operating costs and expenses

283,687,356

212,872,145

203,872,568

Gross profit

196,261,277

34,774,171

15,421,738

Corporate and other costs:

Facilities closing costs

—

217,266

—

Acquisition costs

—

43,464

3,885,666

Stock-based compensation

16,554,898

2,835,971

189,581

Impairment of assets

3,887,216

29,082,203

—

Impairment of goodwill

3,197,391

1,139,297

398,135,038

General and administrative expenses

41,923,972

33,229,718

19,810,607

Total corporate and other costs

65,563,477

66,547,919

422,020,892

Operating income (loss)

130,697,800

(31,773,748)

(406,599,154)

Interest expense, net

19,932,015

16,317,869

12,490,260

Loss on warrant liability

1,608,973

—

—

Other (income) expense

(668,930)

399,182

559,299

Income (loss) before taxes

109,825,742

(48,490,799)

(419,648,713)

Income tax (benefit) expense

15,020,258

(5,067,084)

13,090,905

Net income (loss)

94,805,484

(43,423,715)

(432,739,618)

Less: net income (loss) attributable to noncontrolling interests

42,709,444

2,362,899

(7,959,172)

Net income (loss) attributable to Nutex Health Inc.

$     52,096,040

$   (45,786,614)

$  (424,780,446)

Earnings (loss) per common share

Basic

$              10.23

$            (10.39)

$           (100.36)

Diluted

$                9.69

$            (10.39)

$           (100.36)

 


NUTEX HEALTH INC.


CONSOLIDATED STATEMENTS OF CASH FLOWS


Year ended December 31,


2024


2023


2022


(As restated)

Cash flows from operating activities:

Net income (loss)

$      94,805,484

$    (43,423,715)

$  (432,739,618)

Adjustment to reconcile net income (loss) to net cash from operating
activities:

Depreciation and amortization

18,971,972

17,591,572

13,131,374

Impairment of assets

3,887,216

29,082,203

—

Impairment of goodwill

3,197,391

1,139,297

398,135,038

Derecognition of goodwill

453,017

—

—

Loss on warrant liability

1,608,973

—

—

Stock-based compensation expense

16,554,898

2,835,971

189,581

Rescission of warrant exercise expense

—

—

561,651

Deferred tax (benefit) expense

(13,132,990)

(5,707,323)

4,996,209

Debt accretion expense

1,042,663

1,209,981

1,952,829

Loss on lease termination

—

58,210

—

Non-cash lease expense

(381,035)

131,582

64,143

Changes in operating assets and liabilities:

Accounts receivable

(173,956,924)

(969,761)

56,622,133

Accounts receivable – related party

549,879

(3,613,885)

1,454,934

Inventories

540,770

142,701

(719,107)

Prepaid expenses and other current assets

(7,021,010)

(817,297)

(1,419,139)

Accounts payable

(8,682,179)

(4,715,101)

10,018,100

Accounts payable – related party

(2,037,059)

2,466,536

(329,155)

Accrued arbitration expenses

47,741,815

—

—

Accrued income tax expense

26,532,699

—

—

Accrued expenses and other current liabilities

12,478,227

5,845,481

(1,311,865)

  Net cash from operating activities

23,153,807

1,256,452

50,607,108

Cash flows from investing activities:

Acquisitions of property and equipment

(2,303,897)

(9,496,832)

(14,632,414)

Purchase of restricted short-term investment

(2,940,796)

—

—

Acquired cash in reverse acquisition with Clinigence

—

—

12,716,228

Cash related to sale of business

(361,325)

—

—

Payments for acquisitions of businesses, net of cash acquired

—

(703,893)

—

Cash related to deconsolidation of Real Estate Entities

—

(1,039,157)

(2,421,212)

Net cash from investing activities

(5,606,018)

(11,239,882)

(4,337,398)

Cash flows from financing activities:

Proceeds from lines of credit

2,261,743

2,340,911

2,623,479

Proceeds from notes payable

7,014,999

16,952,905

815,881

Proceeds from convertible notes

—

4,909,864

—

Repayments of lines of credit

(2,079,390)

(1,592,714)

(72,055)

Repayments of notes payable

(9,969,391)

(16,479,512)

(7,237,094)

Repayments of finance leases

(4,628,083)

(3,484,683)

(1,721,224)

Proceeds from common stock issuance, net issuance costs

9,202,500

—

—

Rescission of warrant exercise

—

—

(588,042)

Proceeds from exercise of warrants

2,373,336

—

4,119,141

Proceeds from exercise of options

—

—

644,974

Members’ contributions

3,353,023

298,032

4,513,867

Members’ distributions

(6,437,966)

(5,214,581)

(51,231,657)

Net cash from financing activities

1,090,771

(2,269,778)

(48,132,730)

Net change in cash and cash equivalents and restricted cash

18,638,560

(12,253,208)

(1,863,020)

Cash and cash equivalents and restricted cash – beginning of the year

22,002,056

34,255,264

36,118,284

Cash and cash equivalents and restricted cash – end of the year

$      40,640,616

$      22,002,056

$      34,255,264

Non-GAAP Financial Measures (Unaudited)

EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe EBITDA and Adjusted EBITDA are useful because it allows us to more effectively evaluate our operating performance.

We define EBITDA as net income (loss) attributable to Nutex Health Inc. plus interest expense, income taxes, depreciation and amortization.

We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plus net interest expense, income taxes, depreciation and amortization, further adjusted for stock-based compensation, certain defined items of expense and any acquisition-related costs and impairments. Interest expense includes interest on lease liabilities, which is a component of total finance lease cost. A reconciliation of net income to Adjusted EBITDA is included below.

Adjusted EBITDA is not intended to serve as an alternative to U.S. GAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies. Adjusted EBITDA follows:


Year ended December 31,


2024


2023


2022

Reconciliation of net income (loss) attributable to Nutex Health Inc. to
Adjusted EBITDA:

Net income (loss) attributable to Nutex Health Inc.

$    52,096,040

$   (45,786,614)

$  (424,780,446)

Depreciation and amortization

18,971,972

17,591,572

13,131,374

Interest expense, net

19,932,015

16,317,869

12,490,260

Income tax expense (benefit)

15,020,258

(5,067,084)

13,090,905

Allocation to noncontrolling interests

(7,176,312)

(5,546,263)

(4,837,514)

EBITDA

98,843,973

(22,490,520)

(390,905,421)

Facility closing costs

—

217,266

—

Acquisition costs

—

43,464

3,885,666

Loss on warrant liability

1,608,973

—

—

Stock-based compensation

16,554,898

2,835,971

189,581

Rescission of warrant exercise

—

—

1,243,059

Impairment of assets

3,887,216

29,082,203

—

Impairment of goodwill

3,197,391

1,139,297

398,135,038

Adjusted EBITDA

$  124,092,451

$    10,827,681

$     12,547,923

 


Three months
ended

December 31,
2024


Three months
ended

December 31,
2023


Unaudited


Unaudited

Reconciliation of net income (loss) attributable to Nutex Health Inc. to Adjusted
EBITDA:

Net income (loss) attributable to Nutex Health Inc.

$         61,612,476

$        (31,617,897)

Depreciation and amortization

5,280,488

4,682,724

Interest expense, net

5,052,081

4,236,553

Income tax expense (benefit)

9,152,183

(2,998,554)

Allocation to noncontrolling interests

(2,195,888)

(2,045,390)

EBITDA

78,901,340

(27,742,564)

Loss on warrant liability

536,264

—

Stock-based compensation

14,603,454

637,159

Impairment of assets

(11,640)

29,082,203

Impairment of goodwill

—

1,139,297

Adjusted EBITDA

$         94,029,418

$            3,116,095

About Nutex Health Inc.

Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.

The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states.

The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups.

Forward-Looking Statements

Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act , economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2024 under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.

Cision View original content:https://www.prnewswire.com/news-releases/nutex-health-reports-restated-2024-financial-results-302619344.html

SOURCE Nutex Health, Inc.

Posted on

Clorox Declares Regular Quarterly Dividend of $1.24 Per Share

PR Newswire


OAKLAND, Calif.
, Nov. 18, 2025 /PRNewswire/ — The Clorox Company (NYSE: CLX) announced today that its board of directors has declared a quarterly dividend of $1.24 per share on the company’s common stock. The dividend is payable Feb. 13, 2026, to shareholders of record as of the close of business on Jan. 28, 2026.

Clorox has a long history of providing value to its shareholders through regular dividend payments and annual dividend increases.

About The Clorox Company

The Clorox Company (NYSE: CLX) champions people to be well and thrive every single day. Its trusted brands include Brita®, Burt’s Bees®, Clorox®, Fresh Step®, Glad®, Hidden Valley®, Kingsford®, Liquid-Plumr® and Pine-Sol® as well as international brands such as Clorinda®, Chux® and Poett®. Headquartered in Oakland, California, since 1913, Clorox was one of the first in the U.S. to integrate sustainability into its business reporting. In 2025 the company was ranked No. 1 on Barron’s 100 Most Sustainable Companies list for the third consecutive year. Visit thecloroxcompany.com to learn more.

CLX-C

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/clorox-declares-regular-quarterly-dividend-of-1-24-per-share-302619334.html

SOURCE The Clorox Company

Posted on

Fifth Third Bancorp to Participate in the Goldman Sachs U.S. Financial Services Conference

Fifth Third Bancorp to Participate in the Goldman Sachs U.S. Financial Services Conference

CINCINNATI–(BUSINESS WIRE)–
Fifth Third Bancorp (Nasdaq: FITB) will participate in the 2025 Goldman Sachs U.S. Financial Services Conference on December 10, 2025 at approximately 8:00 AM ET. Tim Spence, chairman, chief executive officer and president, and Bryan Preston, executive vice president and chief financial officer, will represent the Company.

Audio webcast and any presentation slides may be viewed live and for approximately 14 days after the conference through the Investor Relations section of www.53.com. Additionally, any slides used in the presentation will be made available in a printer-friendly format on the Company’s website.

About Fifth Third Bancorp

Fifth Third is a bank that’s as long on innovation as it is on history. Since 1858, we’ve been helping individuals, families, businesses and communities grow through smart financial services that improve lives. Our list of firsts is extensive, and it’s one that continues to expand as we explore the intersection of tech-driven innovation, dedicated people, and focused community impact. Fifth Third is one of the few U.S.-based banks to have been named among Ethisphere’s World’s Most Ethical Companies® for several years. With a commitment to taking care of our customers, employees, communities and shareholders, our goal is not only to be the nation’s highest performing regional bank, but to be the bank people most value and trust.

Fifth Third Bank, National Association is a federally chartered institution. Fifth Third Bancorp is the indirect parent company of Fifth Third Bank and its common stock is traded on the NASDAQ® Global Select Market under the symbol “FITB.” Investor information and press releases can be viewed at www.53.com.

Category: Conferences

Matt Curoe (Investor Relations)

[email protected] | 513-534-2345

Jennifer Hendricks Sullivan (Media Relations)

[email protected] | 614-744-7693

KEYWORDS: Ohio United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo
Posted on

BlackRock® Canada Announces Final November Cash Distributions for the iShares® Premium Money Market ETF

TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) — BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the final November 2025 cash distributions for iShares Premium Money Market ETF. Unitholders of record on November 19, 2025 will receive cash distributions payable on November 28, 2025.

Details regarding the final “per unit” distribution amounts are as follows:

Fund Name Fund Ticker Cash Distribution Per Unit
iShares Premium Money Market ETF CMR $0.075


Further information on the iShares ETFs can be found at http://www.blackrock.com/ca.

About BlackRock
BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate.

About iShares ETFs
iShares unlocks opportunity across markets to meet the evolving needs of investors. With more than twenty years of experience, a global line-up of approximately 1,700 exchange traded funds (ETFs) and approximately US$5.2 trillion in assets under management as of September 30, 2025, iShares continues to drive progress for the financial industry. iShares funds are powered by the expert portfolio and risk management of BlackRock.

iShares® ETFs are managed by BlackRock Canada.

Commissions, trailing commissions, management fees and expenses all may be associated with investing in iShares ETFs. Please read the relevant prospectus before investing. The funds are not guaranteed, their values change frequently and past performance may not be repeated. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional.

Contact for Media:

Sydney Punchard
Email: [email protected]



Posted on

The Campbell’s Company Declares Quarterly Dividend

The Campbell’s Company Declares Quarterly Dividend

CAMDEN, N.J.–(BUSINESS WIRE)–
The Board of Directors of The Campbell’s Company (NASDAQ:CPB) (Campbell’s) today declared a regular quarterly dividend on the company’s capital stock of $0.39 per share. The quarterly dividend is payable Feb. 2, 2026, to shareholders of record at the close of business as of Jan. 8, 2026.

About The Campbell’s Company

For more than 155 years, The Campbell’s Company (NASDAQ:CPB) (Campbell’s) has been connecting people through food they love. Headquartered in Camden, N.J. since 1869, generations of consumers have trusted us to provide delicious and affordable food and beverages. Today, the company is a North American focused brand powerhouse, generating fiscal 2025 net sales of $10.3 billion across two divisions: Meals & Beverages and Snacks. Its portfolio of 16 leadership brands includes Campbell’s, Cape Cod, Chunky, Goldfish, Kettle Brand, Lance, Late July, Pace, Pacific Foods, Pepperidge Farm, Prego, Rao’s, Snack Factory Pretzel Crisps, Snyder’s of Hanover, Swanson and V8. For more information, visit thecampbellscompany.com

Investor Contact:

Rebecca Gardy

(856) 342-6081

[email protected]

Media Contact:

James Regan

(856) 219-6409

[email protected]

KEYWORDS: New York New Jersey United States North America

INDUSTRY KEYWORDS: Retail Convenience Store Manufacturing Supermarket Other Manufacturing Food/Beverage

MEDIA:

Logo
Logo